Michel Finance
Venture Partner @ Truffle Capital
Paris, France
Michel Finance is a Series B investor at Truffle Capital in Paris focused on Marketing and Biotechnology. Michel is CEO and Board member of Theradiag, a company specialized in biotherapy monitoring and diagnostic.Prior to joining Theradiag, Michel was executive VP of Neovacs and Flamel Technologies, both biotech companies listed on Alternext and Nasdaq respectively, CEO of Carmat, an innovative company developing a total artificial heart and listedon Alternext and co-founded by Truffle Capital, Senior Vice President of the Aventis Group, one of the leading pharmaceutical companies in the world, and Senior Vice President and CFO of Sanofi Pasteur, a world leader in vaccines.Michel is also a Director of France Biotech, the French association of entrepreneurs in the biotech sector, and of Carmat and Neovacs.Michel graduated from EM Lyon and is a Certfied Public Accountant. Chevalier de l’ordre national du Mérite.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Michel Finance invests in
Stages Michel Finance invests in
Countries Michel Finance invests in
Investment Focus
Industry
- Marketing 1 (50%)
- Biotechnology 1 (50%)
- Manufacturing 1 (50%)
Stage
- Series B 1 (50%)
- Series C 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Theradiag
|
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. | $5.5M / Series C / Jun 02, 2005 | |
|
Theradiag
|
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. | $10.2M / Series B / May 01, 2003 |
Co-Investors
About Truffle Capital
Truffle Capital is an independent, European venture capital firm focused on disruptive technologies in IT (FinTech and InsurTech) and Life Sciences (BioTech and MedTech). Truffle Capital aims to support the creation and growth of young innovative companies with the potential to become tomorrow’s market leaders. Chaired by Patrick Kron, alongsidethe company’s founders and CEOs, Philippe Pouletty and Bernard-Louis Roques, Truffle Capital raised over $1 billion and has supported over 75 companies since its creation, in the digital technologies and life sciences sectors.At the end of 2017, Truffle Capital successfully completed the first close of its two new institutional funds, Truffle Financial Innovation Fund and Truffle BioMedTech Fund, as well as the first close of a fund dedicated to the French Reserve Fund (« Fonds de Réserve pour les Retraites » or « FRF »).On May 2019, Truffle Capital is a company of 24 professionals from various nationalities (French, Italian, English, Chinese…), passionated by the trade of financing innovation.
Truffle Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Antoine Pau
Partner
|
|||
Faranaz Auliar
Philippe Pouletty Executive Assistant
|
|||
Jean-Claude Caducal
CEO Circle, Life Sciences
|
|||
|
Michel Finance
Venture Partner
|
|||
Miguel Sieler
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michel Finance invest in?
Michel Finance invests primarily in Marketing, Biotechnology and Manufacturing startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michel Finance last invest?
The most recent investment recorded for Michel Finance closed in Jun 2005. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
